Smoldering Myeloma Associated with Zonisamide Treatment
A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (λ) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2002, Vol.41(2), pp.138-141 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 2 |
| container_start_page | 138 |
| container_title | Internal Medicine |
| container_volume | 41 |
| creator | ASAI, Satomi MIYACHI, Hayato KOBAYASHI, Hiroyuki HOTTA, Tomomitsu ANDO, Yasuhiko |
| description | A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (λ) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma. Zonisamide was changed to sodium valproate. Subsequently the M-protein did not increase over 13 months. When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted. (Internal Medicine 41:138-141, 2002) |
| doi_str_mv | 10.2169/internalmedicine.41.138 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2169_internalmedicine_41_138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11868602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-29655c4d90892df610a5d7233341ef1e52b9dace49482f5e462d3025a7d3a3233</originalsourceid><addsrcrecordid>eNplkMtKA0EQRRtRTIz-gs7G5cR-zkwvQ_AFioJx42aodNckHeYRukckf2-HhAR0U7Woc6tuXUJuGB1zluk71_boW6gbtM64FseSjZkoTsiQCanTnAt1SoZUsyLlsQzIRQgrSkWRa35OBowVWZFRPiT5R9PVFr1rF8nrBuuugWQSQmcc9GiTH9cvk6-udQEaZzGZeYS-wba_JGcV1AGv9n1EPh_uZ9On9OXt8Xk6eUmNUqyPxzOljLSaFprbKmMUlI3uhJAMK4aKz7UFg1LLglcKZcatoFxBbgWIyI1IvttrfBeCx6pce9eA35SMltsoyr9RlJKVMYqovN4p19_zODvq9r9H4HYPQDBQVx5a48KRE1lWyFxH7n3HrUIPCzwA4HtnavxngGnNtyb2JXo5oGYJvsRW_AKLpolZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Smoldering Myeloma Associated with Zonisamide Treatment</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>ASAI, Satomi ; MIYACHI, Hayato ; KOBAYASHI, Hiroyuki ; HOTTA, Tomomitsu ; ANDO, Yasuhiko</creator><creatorcontrib>ASAI, Satomi ; MIYACHI, Hayato ; KOBAYASHI, Hiroyuki ; HOTTA, Tomomitsu ; ANDO, Yasuhiko</creatorcontrib><description>A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (λ) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma. Zonisamide was changed to sodium valproate. Subsequently the M-protein did not increase over 13 months. When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted. (Internal Medicine 41:138-141, 2002)</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.41.138</identifier><identifier>PMID: 11868602</identifier><language>eng</language><publisher>Tokyo: The Japanese Society of Internal Medicine</publisher><subject>Adult ; Agammaglobulinemia - blood ; Agammaglobulinemia - chemically induced ; anticonvulsant ; Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Epilepsy, Generalized - drug therapy ; Epilepsy, Generalized - etiology ; Humans ; Immunoglobulin lambda-Chains - blood ; Intracranial Arteriovenous Malformations - complications ; Isoxazoles - adverse effects ; Isoxazoles - therapeutic use ; M-protein ; Male ; Medical sciences ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Multiple Myeloma - blood ; Multiple Myeloma - chemically induced ; Multiple Myeloma - diagnosis ; Myeloma Proteins - analysis ; Pharmacology. Drug treatments ; Subarachnoid Hemorrhage - complications ; Valproic Acid - therapeutic use ; Zonisamide</subject><ispartof>Internal Medicine, 2002, Vol.41(2), pp.138-141</ispartof><rights>The Japanese Society of Internal Medicine</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-29655c4d90892df610a5d7233341ef1e52b9dace49482f5e462d3025a7d3a3233</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13668479$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11868602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ASAI, Satomi</creatorcontrib><creatorcontrib>MIYACHI, Hayato</creatorcontrib><creatorcontrib>KOBAYASHI, Hiroyuki</creatorcontrib><creatorcontrib>HOTTA, Tomomitsu</creatorcontrib><creatorcontrib>ANDO, Yasuhiko</creatorcontrib><title>Smoldering Myeloma Associated with Zonisamide Treatment</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (λ) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma. Zonisamide was changed to sodium valproate. Subsequently the M-protein did not increase over 13 months. When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted. (Internal Medicine 41:138-141, 2002)</description><subject>Adult</subject><subject>Agammaglobulinemia - blood</subject><subject>Agammaglobulinemia - chemically induced</subject><subject>anticonvulsant</subject><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epilepsy, Generalized - drug therapy</subject><subject>Epilepsy, Generalized - etiology</subject><subject>Humans</subject><subject>Immunoglobulin lambda-Chains - blood</subject><subject>Intracranial Arteriovenous Malformations - complications</subject><subject>Isoxazoles - adverse effects</subject><subject>Isoxazoles - therapeutic use</subject><subject>M-protein</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - chemically induced</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Myeloma Proteins - analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Subarachnoid Hemorrhage - complications</subject><subject>Valproic Acid - therapeutic use</subject><subject>Zonisamide</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkMtKA0EQRRtRTIz-gs7G5cR-zkwvQ_AFioJx42aodNckHeYRukckf2-HhAR0U7Woc6tuXUJuGB1zluk71_boW6gbtM64FseSjZkoTsiQCanTnAt1SoZUsyLlsQzIRQgrSkWRa35OBowVWZFRPiT5R9PVFr1rF8nrBuuugWQSQmcc9GiTH9cvk6-udQEaZzGZeYS-wba_JGcV1AGv9n1EPh_uZ9On9OXt8Xk6eUmNUqyPxzOljLSaFprbKmMUlI3uhJAMK4aKz7UFg1LLglcKZcatoFxBbgWIyI1IvttrfBeCx6pce9eA35SMltsoyr9RlJKVMYqovN4p19_zODvq9r9H4HYPQDBQVx5a48KRE1lWyFxH7n3HrUIPCzwA4HtnavxngGnNtyb2JXo5oGYJvsRW_AKLpolZ</recordid><startdate>20020201</startdate><enddate>20020201</enddate><creator>ASAI, Satomi</creator><creator>MIYACHI, Hayato</creator><creator>KOBAYASHI, Hiroyuki</creator><creator>HOTTA, Tomomitsu</creator><creator>ANDO, Yasuhiko</creator><general>The Japanese Society of Internal Medicine</general><general>Japanese Society of Internal Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20020201</creationdate><title>Smoldering Myeloma Associated with Zonisamide Treatment</title><author>ASAI, Satomi ; MIYACHI, Hayato ; KOBAYASHI, Hiroyuki ; HOTTA, Tomomitsu ; ANDO, Yasuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-29655c4d90892df610a5d7233341ef1e52b9dace49482f5e462d3025a7d3a3233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Agammaglobulinemia - blood</topic><topic>Agammaglobulinemia - chemically induced</topic><topic>anticonvulsant</topic><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epilepsy, Generalized - drug therapy</topic><topic>Epilepsy, Generalized - etiology</topic><topic>Humans</topic><topic>Immunoglobulin lambda-Chains - blood</topic><topic>Intracranial Arteriovenous Malformations - complications</topic><topic>Isoxazoles - adverse effects</topic><topic>Isoxazoles - therapeutic use</topic><topic>M-protein</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - chemically induced</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Myeloma Proteins - analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Subarachnoid Hemorrhage - complications</topic><topic>Valproic Acid - therapeutic use</topic><topic>Zonisamide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ASAI, Satomi</creatorcontrib><creatorcontrib>MIYACHI, Hayato</creatorcontrib><creatorcontrib>KOBAYASHI, Hiroyuki</creatorcontrib><creatorcontrib>HOTTA, Tomomitsu</creatorcontrib><creatorcontrib>ANDO, Yasuhiko</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ASAI, Satomi</au><au>MIYACHI, Hayato</au><au>KOBAYASHI, Hiroyuki</au><au>HOTTA, Tomomitsu</au><au>ANDO, Yasuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Smoldering Myeloma Associated with Zonisamide Treatment</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2002-02-01</date><risdate>2002</risdate><volume>41</volume><issue>2</issue><spage>138</spage><epage>141</epage><pages>138-141</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>A 39-year-old man was found to have hyperproteinemia after being treated with zonisamide for 10 years. Laboratory examination revealed a serum M-protein which consisted of IgG (λ) and an increased number of plasma cells in the bone marrow, resulting in a diagnosis of smoldering myeloma. Considering his age, zonisamide was suspected to play an etiologic role in the occurrence of smoldering myeloma. Zonisamide was changed to sodium valproate. Subsequently the M-protein did not increase over 13 months. When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted. (Internal Medicine 41:138-141, 2002)</abstract><cop>Tokyo</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>11868602</pmid><doi>10.2169/internalmedicine.41.138</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2002, Vol.41(2), pp.138-141 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_crossref_primary_10_2169_internalmedicine_41_138 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Agammaglobulinemia - blood Agammaglobulinemia - chemically induced anticonvulsant Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Biological and medical sciences Drug toxicity and drugs side effects treatment Epilepsy, Generalized - drug therapy Epilepsy, Generalized - etiology Humans Immunoglobulin lambda-Chains - blood Intracranial Arteriovenous Malformations - complications Isoxazoles - adverse effects Isoxazoles - therapeutic use M-protein Male Medical sciences Miscellaneous (drug allergy, mutagens, teratogens...) Multiple Myeloma - blood Multiple Myeloma - chemically induced Multiple Myeloma - diagnosis Myeloma Proteins - analysis Pharmacology. Drug treatments Subarachnoid Hemorrhage - complications Valproic Acid - therapeutic use Zonisamide |
| title | Smoldering Myeloma Associated with Zonisamide Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A54%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Smoldering%20Myeloma%20Associated%20with%20Zonisamide%20Treatment&rft.jtitle=Internal%20Medicine&rft.au=ASAI,%20Satomi&rft.date=2002-02-01&rft.volume=41&rft.issue=2&rft.spage=138&rft.epage=141&rft.pages=138-141&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.41.138&rft_dat=%3Cpubmed_cross%3E11868602%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11868602&rfr_iscdi=true |